Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry
  • +38
  • Andrea Chiricozzi,
  • Marina Talamonti,
  • Clara De Simone,
  • Marco Galluzzo,
  • Niccolò Gori,
  • Gabriella Fabbrocini,
  • Angelo Marzano,
  • Giampiero Girolomoni,
  • Anna Maria Offidani,
  • Maria Teresa Rossi,
  • Luca Bianchi,
  • Antonio Cristaudo,
  • Maria Teresa Fierro,
  • Luca Stingeni,
  • Giovanni Pellacani,
  • Giovanni Argenziano,
  • Annalisa Patrizi,
  • Paolo Pigatto,
  • Marco Romanelli,
  • Paola Savoia,
  • Pietro Rubegni,
  • Caterina Foti,
  • Nicola Milanesi,
  • Anna Belloni Fortina,
  • Maria Rita Bongiorno,
  • Teresa Grieco,
  • Sergio Di Nuzzo,
  • Maria Concetta Fargnoli,
  • Andrea Carugno,
  • Alberico Motolese,
  • Franco Rongioletti,
  • Paolo Amerio,
  • Riccardo Balestri,
  • Concetta Potenza,
  • Giuseppe Micali,
  • Cataldo Patruno,
  • Iris Zalaudek,
  • Maurizio Lombardo,
  • Claudio Feliciani,
  • Fabrizio Guarneri,
  • Ketty Peris
Andrea Chiricozzi
Fondazione Policlinico Universitario A. Gemelli IRCCS

Corresponding Author:[email protected]

Author Profile
Marina Talamonti
Policlinico Tor Vergata, Department of Systems Medicine, Tor Vergata University of Rome
Author Profile
Clara De Simone
Fondazione Policlinico Universitario A. Gemelli IRCCS
Author Profile
Marco Galluzzo
Policlinico Tor Vergata, Department of Systems Medicine, Tor Vergata University of Rome
Author Profile
Niccolò Gori
Fondazione Policlinico Universitario A. Gemelli IRCCS
Author Profile
Gabriella Fabbrocini
Section of Dermatology
Author Profile
Angelo Marzano
Università degli Studi di Milano, UOC Dermatologia, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico
Author Profile
Giampiero Girolomoni
University of Verona, Italy
Author Profile
Anna Maria Offidani
Polytechnic University of the Marche Region
Author Profile
Maria Teresa Rossi
ASST Spedali Civili of Brescia, University of Brescia
Author Profile
Luca Bianchi
Policlinico Tor Vergata, Department of Systems Medicine, Tor Vergata University of Rome
Author Profile
Antonio Cristaudo
San Gallicano Dermatological Institute IRCCS
Author Profile
Maria Teresa Fierro
University of Turin
Author Profile
Luca Stingeni
Section of Clinical, Allergological and Venereological Dermatology
Author Profile
Giovanni Pellacani
University of Modena and Reggio Emilia
Author Profile
Giovanni Argenziano
University of Campania, Naples
Author Profile
Annalisa Patrizi
University of Bologna
Author Profile
Paolo Pigatto
University of Milan
Author Profile
Marco Romanelli
University of Pisa
Author Profile
Paola Savoia
Amedeo Avogadro University of Eastern Piedmont
Author Profile
Pietro Rubegni
University of Siena
Author Profile
Caterina Foti
Unit of Dermatology, University of Bari
Author Profile
Nicola Milanesi
University of Florence
Author Profile
Anna Belloni Fortina
University of Padova, Padova, Italy
Author Profile
Maria Rita Bongiorno
University of Palermo
Author Profile
Teresa Grieco
Università degli Studi di Roma La Sapienza
Author Profile
Sergio Di Nuzzo
University of Parma
Author Profile
Maria Concetta Fargnoli
University of L'Aquila Department of Clinical Sciences and Applied Biotechnology
Author Profile
Andrea Carugno
ASST Papa Giovanni XXIII Hospital
Author Profile
Alberico Motolese
Arcispedale Santa Maria Nuova-IRCCS di Reggio Emilia
Author Profile
Franco Rongioletti
University of Cagliari
Author Profile
Paolo Amerio
Gabriele d'Annunzio University of Chieti and Pescara Department of Sciences
Author Profile
Riccardo Balestri
Santa Chiara Hospital
Author Profile
Concetta Potenza
Sapienza University of Rome - Polo Pontino
Author Profile
Giuseppe Micali
University of Catania
Author Profile
Cataldo Patruno
Università degli Studi di Catanzaro Magna Graecia Facoltà di Medicina e Chirurgia
Author Profile
Iris Zalaudek
University of Trieste Clinical Department of Medical Surgical and Health Sciences
Author Profile
Maurizio Lombardo
ASST Sette Laghi, Ospedale di Circolo
Author Profile
Claudio Feliciani
University of Parma
Author Profile
Fabrizio Guarneri
University of Messina Faculty of Medicine and Surgery
Author Profile
Ketty Peris
Fondazione Policlinico Universitario A. Gemelli IRCCS
Author Profile

Abstract

Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection, 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
28 Nov 2020Submitted to Allergy
30 Nov 2020Submission Checks Completed
30 Nov 2020Assigned to Editor
02 Dec 2020Reviewer(s) Assigned
20 Dec 2020Review(s) Completed, Editorial Evaluation Pending
20 Dec 2020Editorial Decision: Revise Minor
24 Dec 20201st Revision Received
28 Dec 2020Submission Checks Completed
28 Dec 2020Assigned to Editor
30 Dec 2020Reviewer(s) Assigned
16 Jan 2021Review(s) Completed, Editorial Evaluation Pending
17 Jan 2021Editorial Decision: Accept